Thursday 19 May, 4 PM CET
IMKE BOONEN
ABSTRACT: Due to the phasing out of amalgam as dental restorative material, the use of resin-based dental composites has increased steadily over the past 25 years. They have been accepted as functional and safe alternatives, even though their biocompatability was never fully characterized. Especially the release of unreacted monomers, and their relation to BPA (a well known estrogenic endocrine disruptor), has raised concern. Therefore, the estrogenic activity of the pure compounds present in these composites, and leachates from cured commercially available composites, was determined using the ERE-CALUX bioassay and will be discussed in this talk.